OZAAM
The Ozaam application gives you faster and more efficient access to property information. You just enter the code written on the estate agent's sign and in a few seconds you can access all the information about the property for sale or to let (photos, price, surface area and description). With just one click, you may arrange a visit with the agency or look up their other similar or different properties.
OZAAM
Industry:
Advertising Platforms Online Portals Real Estate
Founded:
2015-01-01
Address:
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Country:
Belgium
Website Url:
http://www.oza.am
Status:
Closed
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS DMARC OVH Mandrill OVH DNS OzServers DMARC Analyzer
Similar Organizations
Current Employees Featured
Founder
More informations about "Ozaam"
Standard chemotherapy with or without bevacizumab for women …
Background: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …See details»
Treatment algorithm in patients with ovarian cancer
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): …See details»
Standard chemotherapy with or without bevacizumab …
Jun 23, 2015 Prof Amit M Oza, MD a ∙ Adrian D Cook, MSc b ... European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada ... Proc Am Soc Clin …See details»
Bevacizumab in Ovarian Cancer: Results of ICON7 - The ASCO Post
Oct 25, 2015 Oza AM, Cook AD, Pfisterer J, et al: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival …See details»
The World Ovarian Cancer Coalition Every Woman Study: …
Is a not-for-profit organization registered in Canada, comprising 135 patient advocacy group members in 37 countries. It was founded in 2016 by a group of international ovarian cancer …See details»
First-line treatment of women with advanced ovarian cancer: focus …
Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall …See details»
The Role of Maintenance Therapy in Ovarian Cancer
Dr Oza has been a primary investigator and has served on steering and advisory committees for trials from AstraZeneca, Tesaro, and Clovis Oncology. Suggested Readings. Burger RA, …See details»
Distinct roles of treatment schemes and BRCA2 on the restoration …
Introduction. Ovarian cancer is a lethal gynecological malignancy responsible for nearly 5% of cancer deaths, despite accounting for only 2.6% of all gynecological malignancies in the …See details»
Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic …
Jan 12, 2014 Oza AM, Elit L, Tsao M-S, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. Journal of …See details»
Standard chemotherapy with or without bevacizumab for women …
Abstract. Background: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with …See details»
Standard chemotherapy with or without bevacizumab for women …
Oza, AM, Cook, AD, Pfisterer, J et al. (21 more authors) (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall …See details»
Supplementary appendix - The Lancet
Supplement to: Oza AM, Cibula D, Oaknin A, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised Phase II trial ... National Hospital …See details»
Disease-specific ACMG/AMP guidelines improve sequence variant ...
Jul 6, 2021 Shen J, Oza AM, del Castillo I, Duzkale H, Matsunaga T, Pandya A, et al. Consensus interpretation of the p.Met34Thr and p.Val37Ile variants in GJB2 by the ClinGen …See details»
Documents & Announcements - Clinical Genome
Oct 11, 2018 Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT ...See details»
Dr. Lillian Siu - Ontario Institute for Cancer Research
Stockley TL, Oza AM, Berman HK, …, Siu LL, Bedard PL. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret …See details»
ClinGen Expert Clinical Validity Curation of 164 Hearing Loss Gene ...
Mar 21, 2019 PURPOSE: Proper interpretation of genomic variants is critical to successful medical decision making based on genetic testing results. A fundamental prerequisite to …See details»
Epithelial ovarian cancer - The Lancet
Mar 23, 2019 Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert multidisciplinary …See details»
Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer
Nov 14, 2022 The most common one (83% in this report) is the classic-CCOC profile related to ARID1A mutated tumors with enriched expression of canonical CCOC genes involved in …See details»
Organization Of Zambians Abroad
The organization has since become one of the largest Zambian diaspora initiatives with a membership presence in almost all the 50 states of the United States and across the globe. …See details»
Workaround for “Your organization used App Control for Business …
6 days ago After updating to Build 27764 in the Canary Channel, some Windows Insiders are reporting hitting the issue that previously impacted the Dev Channel where an “Your …See details»